NASDAQ:ATAI Atai Beckley Q3 2025 Earnings Results & Report Atai Beckley missed analyst earnings expectations but beat on revenue in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.28 versus the -$0.12 consensus estimate, while revenue of $0.74 million topped the $0.05 million estimate by $0.69 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Atai Beckley EPS ResultsActual EPS-$0.28Consensus EPS -$0.12Beat/MissMissed by -$0.16One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAtai Beckley Revenue ResultsActual Revenue$0.74 millionExpected Revenue$0.05 millionBeat/MissBeat by +$690.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAtai Beckley's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Atai Beckley Q3 2025 Earnings FAQ Did Atai Beckley beat earnings estimates for Q3 2025? Atai Beckley (NASDAQ:ATAI) reported earnings of -$0.28 per share for Q3 2025, missing the consensus estimate of -$0.12. The report was announced on Wednesday, November 12, 2025. What was Atai Beckley's revenue for Q3 2025? Atai Beckley reported revenue of $0.74 million for Q3 2025, against a consensus estimate of $0.05 million. When is Atai Beckley's next earnings date? Atai Beckley's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Atai Beckley on the company's earnings history page. Atai Beckley Earnings HeadlinesEli Lilly Completes Acquisition of AtaiBeckleySeptember 11, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)August 13, 2026 | theglobeandmail.comTHE NEXT GREAT FINANCIAL CRISIS (it’s already here)Weiss Ratings was the only independent firm to warn before the 2008 Financial Crisis. Now it is sounding the alarm again. A new high-risk subprime sector has attracted 3 trillion dollars in investor funds and is already showing signs of collapse, according to the firm. Weiss Ratings outlines five specific steps investors can take to prepare for what could become a severe financial shock.October 10 at 1:00 AM | Weiss Ratings (Ad)AtaiBeckley Inc.August 5, 2026 | cnn.comEli Lilly is acquiring AtaiBeckley for $2.8 billion. Cathie Wood thinks another psychedelic drug stock is an even better betJuly 29, 2026 | msn.comATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli LillyJuly 28, 2026 | globenewswire.comSee More Atai Beckley Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atai Beckley? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atai Beckley and other key companies, straight to your email. Email Address About Atai BeckleyAtaiBeckley AG (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic and other novel therapeutics for mental health conditions. The company was formed through the combination of atai Life Sciences and Beckley Psytech and focuses on treatments intended to address conditions such as depression, anxiety, post-traumatic stress disorder and substance-use disorders. Its development programs include VLS-01, an investigational formulation of N,N-dimethyltryptamine (DMT), and BPL-003, an intranasal formulation of 5-MeO-DMT being studied for conditions including alcohol use disorder and depression. AtaiBeckley also evaluates non-psychedelic compounds and digital or technology-enabled treatment approaches intended to support the development and delivery of mental health therapies. Its products remain investigational and are not broadly approved for commercial use. The company operates internationally, with activities and research programs spanning the United States and Europe. AtaiBeckley is led by co-founder and Chief Executive Officer Florian Brand. Beckley Psytech was founded by Amanda Feilding, whose work in psychedelic research and drug development contributed to the company’s combined platform. View Atai Beckley ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
